<scp>First‐in‐human</scp> study of <scp>JNJ</scp> ‐63709178, a <scp>CD123</scp> / <scp>CD3</scp> targeting antibody, in relapsed/refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

First‐in‐human study of JNJ ‐63709178, a CD123 / CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

Published:2023-01-16 Issue:3 Volume:16 Page:429-435
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Boyiadzis Michael¹,Desai Pinkal²,Daskalakis Nikki³,Donnellan William⁴,Ferrante Lucille³,Goldberg Jenna D.⁵,Grunwald Michael R.⁶,Guttke Christina³,Li Xiang⁵,Perez‐Simon Jose Antonio⁷,Salamero Olga⁸,Tucker Trevor³^ORCID,Xu Xiaoying⁵,Yang Jay⁹,Pemmaraju Naveen¹⁰,Alonso‐Dominguez Juan Manuel¹¹^ORCID

Affiliation:

1. Hillman Cancer Center University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA

2. Weill Cornell Medicine New York‐Presbyterian New York New York USA

3. Janssen Research & Development Spring House Pennsylvania USA

4. Sarah Cannon Research Institute/Tennessee Oncology Nashville Tennessee USA

5. Janssen Research & Development Somerville New Jersey USA

6. Levine Cancer Institute Atrium Health Charlotte North Carolina USA

7. Instituto de Biomedicina de Sevilla (IBIS/CISC) Universitario Virgen del Rocio, Universidad de Sevilla Sevilla Spain

8. Vall d'Hebron University Hospital, VHIO Barcelona Spain

9. Barbara Ann Karmanos Cancer Institute Detroit Michigan USA

10. MD Anderson Cancer Center University of Texas Houston Texas USA

11. Hematology Department, Early Phase Clinical Trials Unit START Madrid‐FJD Fundacion Jiménez Díaz University Hospital Madrid Spain

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13467

Reference11 articles.

1. NIH National Cancer Institure.Cancer Stat Facts: Leukemia—Acute Myeloid Leukemia (AML);2021.https://seer.cancer.gov/statfacts/html/amyl.html

2. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

3. Interleukin‐3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies;Munoz L;Haematologica,2001

4. Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis

5. CD123-targeted therapy in acute myeloid leukemia

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

2. Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment;Frontiers in Pharmacology;2024-08-05

3. Current landscape of CD3 bispecific antibodies in hematologic malignancies;Trends in Cancer;2024-08

4. The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View;Cancers;2024-06-27

5. Bispecific and multispecific antibodies in oncology: opportunities and challenges;Nature Reviews Clinical Oncology;2024-05-31